IP Library › Granted Patent US 10,155,800
Granted Patent B2
US 10,155,800 · App. 15/159,667 · Granted Dec 18, 2018

CTLA4-Ig immunoadhesins

Inventors: Gregory A. Lazar (Arcadia, CA); Matthew J. Bernett (Monrovia, CA)
Assignee: Xencor, Inc.
C07K14/70521C07K16/46C07K19/00A61K38/00C07K2319/30C07K2319/31C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,155,800
App. No.
15/159,667
Granted
Dec 18, 2018
Kind
B2
Abstract

The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.

Claims (9)

1. An immunoadhesin comprising a first domain comprising a variant CTLA4 as compared to SEQ ID NO:6 and a second domain comprising an IgG Fc region, wherein said CTLA4 variant comprises an amino acid modification selected from the group consisting of T51N, A29H, M53Y, L61E, and K93Q, wherein said variant provides enhanced binding to B7-1, B7-2, or both B7-1 and B7-2 as compared to SEQ ID NO:6, and wherein amino acid numbering is according to the EU index.

2. The immunoadhesin of claim 1 , wherein said immunoadhesin has an amino acid sequence selected from the group consisting of SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:37, and SEQ ID NO:38.

3. The immunoadhesin of claim 1 , wherein said variant comprises a combination of substitutions selected from the group consisting of A29H/K93Q, A29H/M53Y, A29H/T51N, T51N/K93Q, T51N/M53Y, A29H/L61E/K93Q, A29H/M53Y/K93Q, A29H/M53Y/L61E, A29H/T51N/L61E, M53Y/L61E/K93Q, T51N/L61E/K93Q, T51N/M53Y/L61E, A29H/M53Y/L61E/K93Q, A29H/T51N/L61E/K93Q, A29H/T51N/M53Y/K93Q, A29H/T51N/M53Y/L61E, T51N/M53Y/L61E/K93Q, and A29H/T51N/M53Y/L61E/K93Q.

4. The immunoadhesin of claim 3 , wherein said variant comprises a combination of substitutions selected from the group consisting of T51N/L61E/K93Q, A29H/T51N/L61E/K93Q, A29H/T51N, T51N/M53Y, and T51N/M53Y/L61E.

5. The immunoadhesin of claim 3 , wherein said variant comprises substitutions A29H/T51N/L61E/K93Q.

6. The immunoadhesin of claim 3 , wherein said variant comprises substitutions T51N/L61E/K93Q.

7. The immunoadhesin of claim 3 , wherein said variant comprises substitutions A29H/T51N.

8. The immunoadhesin of claim 3 , wherein said variant comprises substitutions T51N/M53Y.

9. The immunoadhesin of claim 3 , wherein said variant comprises substitutions T51N/M53Y/L61E.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2016
From: LAZAR, GREGORY A.; BERNETT, MATTHEW
To: XENCOR, INC.
Reel/Frame 038891/0359 →
Continuity (7)
Division 14142705 · Dec 27, 2013
Division 13710305 · Dec 10, 2012
Division 13032491 · Feb 22, 2011
Provisional Application 61412309 · Nov 10, 2010
Provisional Application 61334806 · May 14, 2010
Provisional Application 61306311 · Feb 19, 2010
Related Publication 20160264643A1 · Sep 15, 2016
Cited By (3)
US 12,312,414 US 12,312,415 US 12,486,311